

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 25/04, 43/50, 37/46 // (A01N 43/50, 25:04) (A01N 37/46, 25:04)		A1	(11) International Publication Number: WO 99/65301
			(43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: PCT/US99/09512 (22) International Filing Date: 30 April 1999 (30.04.99) (30) Priority Data: 09/098,842 17 June 1998 (17.06.98) US (71) Applicant (for all designated States except CA MX): UNIROYAL CHEMICAL COMPANY, INC. [US/US]; World Headquarters, Middlebury, CT 06749 (US). (71) Applicant (for CA MX only): GUSTAFSON LLC [US/US]; Suite 400, 1400 Preston Road, Plano, Tx 75093 (US). (72) Inventor: XIE, Min; 3409 Westfield Drive, Plano, TX 75093 (US). (74) Agent: REITENBACH, Daniel; Uniroyal Chemical Company, Inc., World Headquarters, Middlebury, CT 06749 (US).		(81) Designated States: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.	
(54) Title: BIOLOGICALLY-ACTIVE MICRODISPERSION COMPOSITION			
(57) Abstract			
<p>A biologically-active microdispersion of a solid, water-insoluble biologically-active ingredient prepared by a process which comprises: a) liquifying the solid biologically-active ingredient, to produce a liquified biologically-active ingredient; b) mixing the liquified biologically-active ingredient with one or more surfactants and, optionally, one or more cosurfactants, to produce an a.i./surfactant mixture; c) adding water to the a.i./surfactant mixture, to produce a colloidal mixture; and d) equilibrating the colloidal mixture at a temperature at which the biologically-active ingredient is solidified, to produce the biologically-active microdispersion of the solid, water-insoluble biologically-active ingredient.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

BIOLOGICALLY-ACTIVE MICRODISPERSION COMPOSITIONField of the Invention

5 This invention relates to a biologically-active microdispersion composition. More particularly, this invention relates to a water-dilutable clear stable microdispersion comprising a solid, water-insoluble biologically-active ingredient.

10 Background of the Invention

Biologically-active chemicals are often insoluble in water. These chemicals either have to be dissolved in organic solvents or formulated in the form of emulsions or suspensions. Organic solvents are undesirable for
15 environmental and cost reasons. Emulsion and suspension formulations can have limited stability with respect to separation of their components.

In recent years, microemulsions have been used in an attempt to overcome these problems. Microemulsions are a
20 class of colloidal systems which consist of oil, water, and surfactant. As a general rule, oil refers to a water-immiscible liquid.

Water-based microemulsions are particularly desirable because of their increased stability, lack of
25 organic solvent, and ease of use. In water-based microemulsions, the oil phase is dispersed in water such that the dispersed droplets are so small in size (e.g., 10 to 100 nm in diameter) that the microemulsion appears clear or transparent to the naked eye. However, water-
30 based microemulsions are difficult to formulate because for any given oil, a precise surfactant composition is needed to achieve a clear, stable state. Furthermore, the microemulsions can often require a high amount of surfactant compared to the volume of the oil.

35 Most biologically-active ingredients (a.i.) fall into one of two groups: the first group includes those a.i. which are oily liquids at ambient temperature and

are immiscible with water; and the second group includes those a.i. which are solids at ambient temperature and, for all practical purposes, insoluble in water.

To prepare a microemulsion of a solid a.i., the solid a.i. are commonly first dissolved in a non-polar hydrophobic solvent before formulating the a.i. into the microemulsion. However, use of the non-polar hydrophobic solvent is undesirable because the solvents take up room in the microemulsion and they also require the use of more surfactant, creating potential environmental and toxicity problems.

A microdispersion is a colloidal system which is composed of a hydrophobic phase which is finely dispersed in an aqueous phase with the dispersed particles ranging from about 10 to about 500 (typically from about 10 to about 100) nanometers in size. As a result of the very small dispersed particle size, the system visually appears clear to transparent. Unlike microemulsions, the dispersed hydrophobic phase contains solid materials which are not completely solubilized into liquid form. Also unlike microemulsions, microdispersions are usually not thermodynamically stable. However, with proper formulation techniques, microdispersions can retain long-term kinetic stability against the thermodynamically favored crystallization of the solid material out of their dispersed state.

U. S. Patent No. 5,145,684 describes dispersible particles with an average particle size of less than about 400 nm, consisting essentially of a crystalline drug substance having a surface modifier adsorbed on the surface thereof.

U. S. Patent No. 5,306,488 describes a cosmetic composition containing a wax microdispersion in a liquid vehicle.

U. S. Patent No. 5,334,585 describes a pyrethroid microemulsion composition comprising at least one pyrethroid in liquid form, a three-component surfactant

system, and water.

U. S. Patent No. 5,389,688 describes a water based microemulsion comprising a water insoluble agriculturally active ingredient, a surfactant, a lactam, and at least
5 about 80 percent by weight of water.

U. S. Patent No. 5,622,883 describes a nanoparticulate dispersion comprising a surface active surfactant and a pharmaceutical chemical attached to a photographic coupler molecule.

10 European Patent Application 0 648 414 A2 describes a water-dilutable microemulsion comprising an active ingredient, a non-polar water-immiscible solvent, a surfactant system, and water.

15 PCT Application WO 96/08150 describes an aqueous pesticidal microemulsion composition comprising a pesticidally active compound; a surfactant mixture comprising an ethoxylated acid, an alkyl polyglycoside, and an ethoxylated castor oil; and water.

20 It is a purpose of this invention to provide a microdispersion composition consisting of a water-insoluble, solid biologically-active ingredient, a surfactant, an optional cosurfactant, and water.

Summary of the Invention

25 The present invention relates to a biologically-active microdispersion of a solid, water-insoluble biologically-active ingredient prepared by a process which comprises:

30 a) liquifying the solid biologically-active ingredient, to produce a liquified biologically-active ingredient;

b) mixing the liquified biologically-active ingredient with one or more surfactants and, optionally, one or more cosurfactants, to produce an a.i./surfactant
35 mixture;

c) adding water to the a.i./surfactant mixture, to produce a colloidal mixture; and

d) equilibrating the colloidal mixture at a temperature at which the biologically-active ingredient is solidified,

5 to produce the biologically-active microdispersion of the solid, water-insoluble biologically-active ingredient.

10 This invention also relates to an agriculturally-active microdispersion consisting essentially of:

a) a dispersed phase consisting essentially of particles of a solid, water-insoluble agriculturally-active ingredient smaller than 500 nm in size, wherein the concentration of the solid, water-insoluble biologically-active ingredient in the microdispersion is about 0.1 - 40 percent by weight;

b) about 0.1 - 60 percent by weight of a surfactant;

c) optionally, one or more co-surfactants; and

d) water.

Description of the Invention

The term "microdispersion" means a clear or transparent colloidal system comprising a water-insoluble solid finely dispersed in water.

The terms "clear" or "transparent" mean the appearance as a single phase without any particulate or colloidal material or a second phase being present when viewed by the naked eye.

The term "biologically-active ingredient" means any compound or compounds which have biological activity and

- 5 -

are in solid form at room temperature and insoluble in water, such as, for example, pharmaceutically-active compounds and agriculturally-active compounds such as agricultural fertilizers, nutrients, plant growth accelerants, plant growth regulators, or pesticides such as insecticides, miticides, herbicides, fungicides, nematocides, and combinations thereof. Preferably the biologically-active ingredient is an agriculturally-active ingredient.

The abbreviation "a.i." means the biologically-active ingredient.

The term "insoluble" means having a solubility of less than <1% (w/w) at temperatures between about 40°F to about 90°F (about -5°C to about -30°C).

The solid, water-insoluble biologically-active ingredient can be liquified by heating the solid, water-insoluble biologically-active ingredient at a temperature high enough to liquify the solid, water-insoluble biologically-active ingredient. The solid, water-insoluble biologically-active ingredient can also be liquified by dissolving the solid, water-insoluble biologically-active ingredient in a suitable solvent capable of solubilizing the solid biologically-active ingredient, such as, e.g., one or more water-immiscible, volatile solvents capable of dissolving the solid biologically-active ingredient, or one or more surfactants and, optionally, one or more cosurfactants, capable of solubilizing the solid biologically-active ingredient. A combination of heating and dissolution can also be used to liquify the solid biologically-active ingredient.

The surfactant or mixture of surfactant and cosurfactant preferably have a hydrophilic-lipophilic

- 6 -

balance (HLB) within a specified range. By "hydrophilic-lipophilic balance" is meant an empirical quantity, on an arbitrary scale, which is a measure of the polarity of a surfactant or mixture of surfactants. See P. Becher et al., "Nonionic Surfactant, Physical Chemistry," Marcel Dekker, N.Y. (1987), pages 439-456. It is a widely known and used term.

The surfactant, or more preferably, the mixture of surfactant and cosurfactant, should be chosen from those having a resulting HLB value in the range of from about 7 to about 16, more preferably about 8 to about 13. When a mixture of surfactant and cosurfactant is employed, while one of the components may have a value outside the desired range, e.g., below about 5, it will be understood that by mixing in surfactant and/or cosurfactant with HLB's greater than, e.g., about 9, the resulting combined HLB value will be in the range of 7 to 16. Also, it is desirable that at least one of the surfactants have a molecular weight of at least about 500, although this weight is not critical.

Surfactants which can be employed include both ionic agents, i.e., cationic, anionic or zwitterionic, and non-ionic agents, or mixtures thereof. Examples of cationic surfactants include alkylamines such as C_{12} - C_{18} fatty amines, e.g., dimethyl lauramine, and ethoxylated amines such as ethoxylated C_8 - C_{18} fatty amines, e.g., PEG-15 tallow amine.

Examples of anionic surfactants include C_8 - C_{32} alkanoic acids and salts thereof; carboxylic acid esters such as C_5 - C_{29} monoesters of lactic acid; carboxylic acid ethers such as nonoxynol 8 carboxylic acid; phosphoric acid esters and salts including such phospholipids as phosphatidic acid and phosphatidyl serine; C_3 - C_{20} sulfonates, including alkyl-, olefin-, and alkylaryl derivatives; sulfuric acid esters such as alkyl sulfates and alkyl ether sulfates; and betaine derivatives.

- 7 -

Among the non-ionic surfactants which can be employed are C₁₀-C₄₀ alcohols; alkanolamides; ethoxylated carboxylic acid esters; ethoxylated glycerides such as ethoxylated castor oil; C₅-C₂₉ monoglycerides and ethoxylated derivatives thereof; C₂₀-C₁₃₀ sorbitol and sorbitan monoesters, diesters, and triesters, and polyoxyethylene (POE) derivatives thereof having 0 to 90 POE groups, e.g., polyoxyethylene sorbitan monooleate, sorbitol hexaoleate POE (50); trialkyl phosphate esters; ethoxylated alcohols; ethoxylated polysiloxanes; propoxylated POE ethers; and alkylpolyglycosides. (See, e.g., Surfactant Encyclopedia, Martin M. Rieger, 1993, published by Cosmetics & Toiletries magazine/Allured Publishing Corporation, Wheaton, IL)

As stated above, the molecular weight of these surfactants is not critical, but it is desirable that at least one of them have a molecular weight of at least about 500, more preferably greater than about 750.

A preferred surfactant is an ethoxylated castor oil (HLB about 10-16). The ethoxylated castor oil has preferably from between about 5 to 55 moles of ethylene oxide, more preferably, from between about 30 to 40 moles of ethylene oxide, chemically combined with each mole of castor oil. Examples of suitable ethoxylated castor oils useful in this invention include, e.g., PEG 25, PEG 30, PEG 36, PEG 40, and PEG 50 castor oil.

Preferably, the weight ratio (w/w) of the solid, water-insoluble biologically-active ingredient to the surfactant is between about 2:1 and 1:2, more preferably, between about 1.1:1 and 1:1.1, and most preferably, about 1:1.

For the purposes of this invention, the term "cosurfactant" means any compound which assists the surfactant in lowering the interfacial tension between the hydrophobic and hydrophilic phases. Such compounds typically show some miscibility with both the hydrophobic

- 8 -

and hydrophilic phases, and comprise some polar bonds, such as, e.g., C-O, N-H, O-H, C-Cl, F-H, N=O, and C=O. Compounds useful as cosurfactants in the microdispersion of this invention include sorbitol, ethylene glycol, polyethylene glycol (PEG), mannitol, propylene glycol, monoalkyl ethers, and mono- and di-saccharides, medium fatty alcohols, acids or amines. Examples of suitable cosurfactants include, e.g., sorbitan monooleate, heptyl acetate, methyl-pyrrolidone, butyrolactone, octyl-pyrrolidone, EO/PO block copolymer, propylene glycol, and the like. The total amount of cosurfactant or cosurfactants present in the microdispersion of this invention is preferably from about 5 to about 30 percent by weight, more preferably from about 10 to about 20 percent by weight. Preferably, one or two cosurfactants are present in the microdispersion of this invention. Preferably, the weight ratio (w/w) of the surfactant to the cosurfactant is between about 4:1 and 1:4, more preferably, between about 3:1 and 1:3.

Water is present in the microdispersion in amounts preferably ranging from about 10 to about 80 percent by weight, more preferably from about 20 to about 50 percent by weight.

The present invention preferably relates to a biologically-active microdispersion of a solid, water-insoluble biologically-active ingredient prepared by a process which comprises:

a) heating the solid biologically-active ingredient at a temperature sufficiently high enough to liquify the biologically-active ingredient, to produce a liquified biologically-active ingredient;

b) mixing the liquified biologically-active ingredient with one or more surfactants and, optionally, one or more cosurfactants, to produce an a.i./surfactant mixture;

- 9 -

c) adding water to the a.i./surfactant mixture, to produce a colloidal mixture;

d) cooling the colloidal mixture to a temperature at which the biologically-active ingredient solidifies,

5

to produce the biologically-active microdispersion of the solid, water-insoluble biologically-active ingredient.

10 The present invention additionally preferably relates to a biologically-active microdispersion of a solid, water-insoluble biologically-active ingredient prepared by a process which comprises:

15 a) mixing the solid biologically-active ingredient with one or more surfactants and, optionally, one or more cosurfactants, capable of solubilizing the solid biologically-active ingredient, to solubilize the biologically-active ingredient, to produce an a.i./surfactant mixture; and

20 b) adding water to the a.i./surfactant mixture,

20

to produce the biologically-active microdispersion of the solid, water-insoluble biologically-active ingredient.

25 The present invention further preferably relates to a biologically-active microdispersion of a solid, water-insoluble biologically-active ingredient prepared by a process which comprises:

30 a) dissolving the solid biologically-active ingredient in a water-immiscible, volatile solvent capable of dissolving the solid biologically-active ingredient, to produce an a.i./solvent mixture;

b) adding one or more surfactants and, optionally, one or more cosurfactants, to the a.i./solvent mixture, to produce an a.i./solvent/surfactant mixture;

35

c) adding water to the a.i./solvent/surfactant mixture, to produce a colloidal mixture;

- 10 -

d) heating the colloidal mixture at a temperature and at a pressure sufficient to evaporate the solvent, to produce the biologically-active microdispersion of the solid, water-insoluble biologically-active ingredient.

The present invention also preferably relates to a biologically-active microdispersion of a solid, water-insoluble biologically-active ingredient prepared by a process which comprises:

a) heating the solid biologically-active ingredient in the presence of one or more surfactants and, optionally, one or more cosurfactants, at a temperature sufficiently high enough to liquify the biologically-active ingredient, to produce an a.i./surfactant mixture;

b) adding water to the a.i./surfactant mixture, to produce a colloidal mixture; and

c) cooling the colloidal mixture to a temperature at which the biologically-active ingredient solidifies,

to produce the biologically-active microdispersion of the solid, water-insoluble biologically-active ingredient.

The biologically-active microdispersion of this invention can be prepared as follows:

A. The solid biologically-active ingredient is heated at a temperature sufficiently high enough to liquify the biologically-active ingredient, to produce a liquified biologically-active ingredient. Although there is no particular criticality to the sequence of addition and mixing, the liquified biologically-active ingredient is then typically mixed with one or more surfactants and, optionally, one or more cosurfactants, to produce an a.i./surfactant mixture. Water is then added to the

- 11 -

a.i./surfactant mixture, preferably with agitation, to produce a colloidal mixture. Finally, the colloidal mixture is cooled to a temperature at which the biologically-active ingredient solidifies, to produce the microdispersion. This method is particularly suitable if the solid a.i. is not soluble in the surfactant or surfactant/cosurfactant mixture.

B. The solid biologically-active ingredient is mixed with one or more surfactants and, optionally, one or more cosurfactants, capable of solubilizing the solid biologically-active ingredient, to produce an a.i./surfactant mixture. Water is then added to the a.i./surfactant mixture, preferably with agitation, to produce the microdispersion. This method is particularly suitable if the solid a.i. is soluble in the surfactant or in the surfactant/cosurfactant mixture.

C. The solid biologically-active ingredient is dissolved in a water-immiscible, volatile solvent capable of dissolving the solid biologically-active ingredient, such as, e.g., methylene chloride, ethyl acetate, and certain short-chain hydrocarbons such as hexane, heptane, or octane, to produce an a.i./solvent mixture. One or more surfactants and, optionally, one or more cosurfactants, are then added to the a.i./solvent mixture, preferably with agitation, to produce an a.i./solvent/surfactant mixture. Water is then added to the a.i./solvent/surfactant mixture, preferably with agitation, to produce a colloidal mixture. Finally, the colloidal mixture is heated at a sufficiently high temperature and/or exposed to a sufficiently reduced pressure, to evaporate the solvent, to produce the microdispersion.

D. A combination of Methods A and B can be used to

- 12 -

prepare the microdispersion of this invention. This method consists of the following steps:

5 The solid biologically-active ingredient is heated in the presence of one or more surfactants and, optionally, one or more cosurfactants, preferably with agitation, at a temperature sufficiently high enough to liquify the biologically-active ingredient, to produce an a.i./surfactant mixture. Water is then added to the a.i./surfactant mixture, preferably with agitation, to
10 produce a colloidal mixture. Finally, the colloidal mixture is cooled to a temperature at which the biologically-active ingredient solidifies, to produce the microdispersion.

15 The agriculturally-active microdispersion of this invention preferably consists essentially of:

a) a dispersed phase consisting essentially of particles of a solid, water-insoluble agriculturally-active ingredient from about 10 to about 100 nm in size, wherein the concentration of the solid, water-insoluble agriculturally-active ingredient in the microdispersion is about 10 - 40 percent by weight, more preferably about
20 15 - 35 percent by weight;

25 b) about 10 - 40 percent by weight, more preferably about 20 - 40 percent by weight, of a surfactant, preferably, an ethoxylated castor oil;

30 c) optionally, one or more co-surfactants; and

d) water.

35 The following examples are provided to illustrate this invention.

- 13 -

EXAMPLES**Example 1**

The microdispersions of Table 1 below were prepared
as follows:

Ingredients

Imazalil: 1-[(2,4-dichlorophenyl)-2-(2-propenyloxy)-
ethyl]-1H-imidazole; mp 50-55°C; (Janssen Pharmaceutica)

Metalaxyl: N-(2,6-dimethylphenyl)-N-(methoxy-
acetyl)-alanine methyl ester; mp 71.8-72.3°C (Ciba)

Ethoxylated Castor Oil: (Witco)

Sorbitan Monooleate: Span 80 (ICI)

Heptyl Acetate: Exxate 700 (Exxon)

Methyl Pyrrolidone: AgsolEx 1 (ISP)

Butyrolactone: (ISP)

Octyl Pyrrolidone: AgsolEx 8 (ISP)

EO/PO Block Copolymer: Pluronic 17R2 (BASF)

Preparation:**A. Preparation of Microdispersions Nos. 1 and 2**

Imazalil and PEG 40 castor oil were combined in a
beaker and heated on a hot plate at 60°C with stirring
until the mixture became a clear liquid. Water was then
added to the mixture with stirring. A clear to turbid to
clear phase transition of the mixture was observed during
the water addition. The resultant mixture was then
cooled to room temperature to produce a clear,
homogeneous, amber-colored microdispersion.

B. Preparation of Microdispersions Nos. 3 - 20

All the ingredients except water were combined in a
beaker and heated at 50°C in an oven for one hour. The
resultant mixture was then stirred until no solid
materials were present. If solid persisted, the mixture
was reheated in the oven at 50°C and stirred until no

- 14 -

solid was present. Water was then added with stirring to the mixture. In most cases, a clear to turbid to clear phase transition of the mixture was observed during the water addition. The resultant mixture was then cooled to room temperature to produce a clear, homogeneous, amber-colored microdispersion.

5

- 15 -

Table 1

Ingredient	Microdispersion No. (Weight Percent)									
	1	2	3	4	5	6	7	8	9	10
Imazalil	8.3	36.1	31.7	31.7	31.5	31.8	31.8	31.8	--	--
Metalaxyl	--	--	--	--	--	--	--	--	20.0	20.0
Ethoxylated Castor Oil (PEG-40)	11.4	35.8	--	--	28.0	--	--	31.0	20.0	20.0
Ethoxylated Castor Oil (PEG-36)	--	--	31.0	31.0	--	31.0	30.9	--	--	--
Sorbitan Monooleate	--	--	12.8	--	--	--	--	--	--	--
Heptyl Acetate	--	--	--	12.8	--	--	--	--	--	10.0
Methyl-Pyrrolidone	--	--	--	--	12.8	--	--	--	--	--
Butyrolactone	--	--	--	--	--	12.7	--	--	20.0	20.0
Octyl-Pyrrolidone	--	--	--	--	--	--	12.8	--	--	--
EO/PO Block Copolymer (MW 2150)	--	--	--	--	--	--	--	--	10.0	--
Propylene Glycol	--	--	--	--	--	--	--	13.5	--	--
Water	80.3	28.3	24.5	24.5	27.7	24.5	24.5	23.7	30.0	30.0

Table 1 (continued)

Ingredient	Microdispersion No. (Weight Percent)									
	11	12	13	14	15	16	17	18	19	20
Imazalil	--	--	29.9	32.2	26.1	23.2	20.9	31.5	31.5	--
Metalaxyl	20.0	20.0	--	--	--	--	--	--	--	18.2
Ethoxylated Castor Oil (PEG-40)	20.0	20.0	29.4	31.7	25.8	22.9	20.6	31.0	31.0	18.2
Ethoxylated Castor Oil (PEG-36)	--	--	--	--	--	--	--	--	--	--
Sorbitan Monooleate	--	--	--	--	--	--	--	--	--	--
Heptyl Acetate	--	--	--	--	--	--	--	--	--	--
Methyl-Pyrrolidone	--	--	--	--	--	--	--	--	--	--
Butyrolactone	20.0	20.0	12.1	13.1	10.6	9.5	8.5	--	12.8	28.9
Octyl-Pyrrolidone	11.0	--	--	--	--	--	--	12.8	--	--
EO/PO Block Copolymer (MW 2150)	--	--	--	--	--	--	--	--	--	--
Propylene Glycol	--	--	--	--	--	--	--	--	--	--
Water	40.0	28.8	23.0	23.0	37.5	44.4	50.0	24.7	24.7	34.7

- 17 -

Table 2
Stability of Undiluted Microdispersions

Microdispersion No.	Stability
1	Clear and homogeneous liquid at room temperature (RT) for 26 days; some crystal growth after 26 days
2	Clear and homogeneous liquid at RT and -6°C for at least 7 days; some crystal growth after 8 months at RT
3	Clear and homogenous liquid at RT for at least 8 months
4	Clear and homogenous at time of preparation; no stability data
5	Clear and homogeneous liquid at both RT and at -6°C for at least 2 weeks; crystal growth after 1 month storage at RT
6	Clear and homogeneous liquid at both RT and at 40°C for at least 8 months; did not freeze or show crystal growth after 1 month at -7°C
7	Clear and homogeneous liquid at RT for at least 7 months; did not freeze or show crystal growth after 1 month at -5°C
8	Clear and homogeneous liquid at RT for at least 8 months; did not freeze or show crystal growth after 1 month at -7°C
9	Clear and homogeneous liquid at RT for at least 7 months; stable after 1 month storage at 40°C ; reconstituted to a clear and homogenous liquid after 3 freeze/thaw cycles
10	Clear and homogeneous liquid at RT for at least 7 months; stable after 1 month storage at 40°C ; reconstituted to a clear and homogenous liquid after 3 freeze/thaw cycles
11	Clear and homogeneous liquid at RT for at least 7 months; stable after 1 month storage at 40°C ; reconstituted to a clear and homogenous liquid after 3 freeze/thaw cycles
12	Clear and homogeneous liquid at RT for at least 7 months; stable after 1 month storage at 40°C ; reconstituted to a clear and homogenous liquid after 3 freeze/thaw cycles
13	Clear and homogeneous liquid at RT for at least 3 days
14	Clear and homogeneous liquid at RT for at least 3 days

- 18 -

Table 2 (continued)

Microdispersion No.	Stability
15	Clear and homogeneous liquid at RT for at least 3 days
16	Clear and homogeneous liquid at RT for at least 3 days
17	Clear and homogeneous liquid at RT for at least 3 days
18	Clear and homogeneous liquid at RT for at least 2 years; clear and homogeneous liquid at 40°C for at least 7 months; clear and homogeneous liquid at -5°C for at least 1 month; did not freeze after one month at -5°C ; reconstituted after 1 freeze/thaw cycle (24 hours at -20°C to 24 hours at RT); median particle size was determined to be 76 nm by Laser Scattering Particle Size Distribution Analyzer, Horiba LA-910
19	Clear and homogeneous liquid at RT for at least 26 months; clear and homogeneous liquid at 40°C for at least 26 months; did not freeze or show crystals after 1 month at -7°C ; reconstituted after 1 freeze/thaw cycle (24 hours at -20°C to 24 hours at RT); separated a slightly turbid top layer after 2 months at 50°C but became clear and homogeneous again upon returning to RT
20	Clear and homogeneous liquid at RT, 40°C, 50°C, and -20°C for at least 1 month

Certain of Microdispersions Nos. 1-20 were diluted with water to determine their stability in diluted form. Table 2A below describes the stability of various dilutions of certain of the microdispersions. All dilutions were clear at the time of dilution (i.e., day 0).

- 19 -

Table 2A

Microdispersion No.	% Conc. in Water (w/w)	Dilution Stability
5	1	After 3 days, appearance changed from clear to translucent to turbid but remained homogeneous and showed no crystals
5	10	"
6	1	Clear and homogeneous for at least 7 days
6	5	"
7	5	During 8 day storage, changed from transparent to translucent but remained homogeneous and showed no crystals
8	5	"
9	5	Stable for at least 20 days
9	50	Clear and stable against crystallization for 2 days
10	5	Transparent and homogeneous for 3 days; showed some phase separation on day 7 but was reconstituted with shaking and was stable against crystallization for at least 20 days
10	50	Phase separation after 2 days but was reconstituted with shaking and was stable against crystallization for at least 20 days
11	2	Clear and homogeneous for at least 1 month
11	5	"
11	10	"
11	20	"
11	33	"
11	50	"
12	5	Showed crystals on day 3
12	50	Showed crystals on day 2
18	1	Clear and homogeneous for at least 8 months
18	3	"

Table 2A (continued)

Microdispersion No.	% Conc. in Water (w/w)	Dilution Stability
18	6.7	"
18	14	"
18	25	"
19	5	Clear and stable for at least 3 days
20	2	Clear and homogeneous for at least 8 days
20	5	"
20	10	"
20	20	"
20	33	"
20	50	"

- 21 -

Example 2Determination of Fungicidal Activity Using NSL+ Screen

Microdispersions Nos. 18 and 19 were each applied to two varieties of Barley seed (Harrington and Steptoe) and Wheat seed (Stephens) at a rate of 0.5 fl oz/100 pounds of seed ("cwt").

One (1) month after treatment, the treated seeds were planted in a natural sandy loam (NSL) mixture composed of a 1:1 mixture of sand to loam, in which the loam is infested with *Pythium spp.* and *Fusarium graminearum* fungi. The planted seeds were placed into a 10°C atmosphere to allow for *Pythium* pressure. After 10 days, the seeds were moved to a greenhouse (27°C) for seedling emergence and survival evaluation. All treatments were replicated five times and placement in the greenhouse was randomized.

An untreated control in which untreated seeds were planted in the NSL was included for each seed variety. A sterile control consisting of untreated seeds being planted in a sterilized NSL mixture was also included for each seed variety.

Table 3 below shows the results of the above NSL+ Screen. Percent stand (% Stand) was determined by the formula:

$$\frac{\text{Seeds germinated}}{\text{Seeds planted}} \times 100 = \% \text{ Stand}$$

- 22 -

Table 3
NSL+ Screen (% Stand)

Test Cmpd.	Barley (Harrington) (DAP) ¹			Barley (Steptoe) (DAP)			Wheat (Stephens) (DAP)		
	3	14	21	3	14	21	3	14	21
UTC ²	75	60	47	59	44	35	16	10	9
18	79	79	72	78	77	61	50	42	28
19	83	70	60	88	89	82	44	36	32
Sterile ³	69	72	72	97	100	100	91	96	96

¹ Days after planting

² Untreated control

³ Sterile control

Example 3

Determination of Fungicidal Activity Using *Pythium* *Ultimum* Screen

Microdispersion No. 20 was compared to the untreated control according to the following procedure:

Microdispersion No. 20 was applied to cotton seed (DP50) at the concentrations listed below in Table 4. Known amounts of the pathogen *Pythium Ultimum* were incorporated into a sterile 1:1 mixture of sand and loam. The treated and untreated cotton seeds were placed into flats containing the inoculated soil mixture and placed in a 20°C environment for seedling emergence and survival evaluation. All treatments were replicated five (5) times and placement in the greenhouse was randomized.

Table 4 shows the results of the above *Pythium Ultimum* Screen.

- 23 -

Table 4
Pythium Ultimum Screen
(% Stand on Day 21)¹

Concentration (ppm)	% Stand
37.5	58
75	77
100	65
150	71

¹ % Stand of untreated control was 0%

- 24 -

What is claimed is:

1. A process for preparing a biologically-active microdispersion of a solid, water-insoluble biologically-active ingredient which process comprises:

a) liquifying the solid biologically-active ingredient, to produce a liquified biologically-active ingredient;

b) mixing the liquified biologically-active ingredient with one or more surfactants and, optionally, one or more cosurfactants, to produce an a.i./surfactant mixture;

c) adding water to the a.i./surfactant mixture, to produce a colloidal mixture; and

d) equilibrating the colloidal mixture at a temperature at which the biologically-active ingredient is solidified,

to produce the biologically-active microdispersion of the solid, water-insoluble biologically-active ingredient.

2. A process as recited in claim 1 wherein the biologically-active ingredient is an agriculturally-active ingredient.

3. A biologically-active microdispersion prepared by the process as recited in claim 1.

4. A process as recited in claim 1, wherein the process comprises:

a) heating the solid biologically-active ingredient at a temperature sufficiently high enough to liquify the biologically-active ingredient, to produce a liquified biologically-active ingredient;

b) mixing the liquified biologically-active

- 25 -

ingredient with one or more surfactants and, optionally, one or more cosurfactants, to produce an a.i./surfactant mixture;

5 c) adding water to the a.i./surfactant mixture, to produce a colloidal mixture;

d) cooling the colloidal mixture to a temperature at which the biologically-active ingredient solidifies,

10 to produce the biologically-active microdispersion of the solid, water-insoluble biologically-active ingredient.

15 5. A process as recited in claim 4 wherein the biologically-active ingredient is an agriculturally-active ingredient.

6. A process as recited in claim 5 wherein the one or more surfactants is an ethoxylated castor oil.

20 7. A biologically-active microdispersion prepared by the process as recited in claim 4.

8. A process as recited in claim 1 wherein the process comprises:

25 a) mixing the solid biologically-active ingredient with one or more surfactants and, optionally, one or more cosurfactants, capable of solubilizing the solid biologically-active ingredient, to solubilize the biologically-active ingredient, to produce an a.i./surfactant mixture; and

30 b) adding water to the a.i./surfactant mixture,

to produce the biologically-active microdispersion of the solid, water-insoluble biologically-active ingredient.

35 9. A process as recited in claim 8 wherein the biologically-active ingredient is an agriculturally-

- 26 -

active ingredient.

10. A process as recited in claim 9 wherein the one or more surfactants is an ethoxylated castor oil.

11. A microdispersion prepared by the process as recited in claim 8.

12. A process as recited in claim 1 wherein the process comprises:

a) dissolving the solid biologically-active ingredient in a water-immiscible, volatile solvent capable of dissolving the solid biologically-active ingredient, to produce an a.i./solvent mixture;

b) adding one or more surfactants and, optionally, one or more cosurfactants, to the a.i./solvent mixture, to produce an a.i./solvent/surfactant mixture;

c) adding water to the a.i./solvent/surfactant mixture, to produce a colloidal mixture;

d) heating the colloidal mixture at a temperature and at a pressure sufficient to evaporate the solvent,

to produce the biologically-active microdispersion of the solid, water-insoluble biologically-active ingredient.

13. A process as recited in claim 12 wherein the biologically-active ingredient is an agriculturally-active ingredient.

14. A process as recited in claim 13 wherein the one or more surfactants is an ethoxylated castor oil.

15. A biologically-active microdispersion prepared by the process as recited in claim 12.

16. A process as recited in claim 1 wherein the

- 27 -

process comprises:

a) heating the solid biologically-active ingredient in the presence of one or more surfactants and, optionally, one or more cosurfactants, at a temperature sufficiently high enough to liquify the biologically-active ingredient, to produce an a.i./surfactant mixture;

b) adding water to the a.i./surfactant mixture, to produce a colloidal mixture; and

c) cooling the colloidal mixture to a temperature at which the biologically-active ingredient solidifies,

to produce the biologically-active microdispersion of the solid, water-insoluble biologically-active ingredient.

17. A process as recited in claim 16 wherein the biologically-active ingredient is an agriculturally-active ingredient.

18. A process as recited in claim 17 wherein the one or more surfactants is an ethoxylated castor oil.

19. A biologically-active microdispersion prepared by the process as recited in claim 16.

20. A clear agriculturally-active microdispersion consisting essentially of:

a) a dispersed phase consisting essentially of particles of a solid, water-insoluble agriculturally-active ingredient smaller than 500 nm in size, wherein the concentration of the solid, water-insoluble agriculturally-active ingredient in the microdispersion is about 0.1 - 40 percent by weight;

b) about 0.1 - 60 percent by weight of a

- 28 -

surfactant;

c) optionally, one or more co-surfactants; and

5 d) water.

21. An agriculturally-active microdispersion as recited in claim 20 consisting essentially of:

10 a) a dispersed phase consisting essentially of particles of a solid, water-insoluble agriculturally active ingredient from about 10 to about 100 nm in size, wherein the concentration of the solid, water-insoluble agriculturally active ingredient in the microdispersion
15 is about 10 - 40 percent by weight;

b) about 10 - 40 percent by weight of a surfactant;

20 c) optionally, one or more co-surfactants; and

d) water.

22. A agriculturally-active microdispersion as
25 recited in claim 21 wherein the concentration of the solid, water-insoluble agriculturally-active ingredient in the microdispersion is about 15 - 35 percent by weight.

30 23. A agriculturally-active microdispersion as recited in claim 21 wherein the surfactant is an ethoxylated castor oil.

35 24. An agriculturally-active microdispersion as recited in claim 23 wherein the concentration of the ethoxylated castor oil in the microdispersion is about 20

- 29 -

- 40 percent by weight.

5 25. An agriculturally-active microdispersion as
recited in claim 24 wherein the cosurfactant is selected
from group consisting of sorbitan monooleate, heptyl
acetate, methyl-pyrrolidone, butyrolactone, octyl-
pyrrolidone, EO/PO block copolymer, and propylene glycol.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/09512

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A01N25/04 A01N43/50 A01N37/46 //(A01N43/50,25:04),
(A01N37/46,25:04)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 23590 A (LEECH WAYNE FREDERICK ;MCLAREN DONALD GEORGE (NZ); BOMAC LAB LTD () 8 September 1995 (1995-09-08) page 2, line 30 - page 3, line 15 page 3, line 26 - page 4, line 4 page 4, line 11 - line 14 claims 1,7,11	1-11, 16-25
Y		6,10,14, 18,23-25
X	FR 1 026 727 A (R.DECKER ET AL.) 6 May 1953 (1953-05-06) page 1, column 1, paragraph 5 page 2, column 1, line 11 claim 1	1-5,7, 16,17, 19-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 August 1999

Date of mailing of the international search report

26/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lamers, W

INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/US 99/09512

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 15 67 085 A (POITEVINE) 18 December 1969 (1969-12-18) page 1, paragraph 1 page 10, paragraph 3 page 10, line 24 - line 25 page 14, line 7 - line 9 page 23; example 7 ----	20-25
X	GB 828 414 A (ICI) page 1, column 1, line 11 - line 13 page 1, column 1, line 40 - column 2, line 63 ----	1-5,7, 16,17,19
Y	WO 94 20072 A (PHARMACIA AB ;WESTESEN KIRSTEN (DE); SIEKMANN BRITTA (DE)) 15 September 1994 (1994-09-15) page 2, line 11 - page 12 page 10, line 28 - page 11, line 2 page 11, line 12 page 12, line 17 - line 19 page 21, line 22 - line 28 page 23, line 15 - line 21 page 24, line 1 - line 8 page 49; example 35 ----	1-25
Y	EP 0 404 210 A (BIOTECHNICA DIAGNOSTICS INC) 27 December 1990 (1990-12-27) page 3, line 4 - line 16 page 4, line 20 - line 36 ----	1-5,7, 16,17, 19-22
Y	EP 0 300 691 A (CHINOIN GYOGYSZER ES VEGYESZET) 25 January 1989 (1989-01-25) page 3, line 1 - line 6 page 4, line 5 - line 10 ----	1-3,8,9, 11
Y	US 2 420 295 A (G.F.BIEHN ET AL.) 13 May 1947 (1947-05-13) column 3, line 25 - line 37 -----	1-3,12, 13,15

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/US 99/09512

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9523590 A	08-09-1995	NZ 260018 A AU 697636 B AU 1863995 A BR 9506488 A CA 2179892 A EP 0748211 A US 5925374 A ZA 9501804 A	26-10-1995 15-10-1998 18-09-1995 07-10-1997 08-09-1995 18-12-1996 20-07-1999 08-12-1995
FR 1026727 A	06-05-1953	NONE	
DE 1567085 A	18-12-1969	BE 645497 A CH 419726 A FR 1349176 A GB 1027699 A NL 295584 A	16-07-1964 22-04-1964
GB 828414 A		NONE	
WO 9420072 A	15-09-1994	CA 2091152 A AU 676279 B AU 6225394 A EP 0687172 A FI 954143 A JP 8507515 T NO 953461 A NZ 262541 A US 5785976 A US 5885486 A	06-09-1994 06-03-1997 26-09-1994 20-12-1995 19-10-1995 13-08-1996 06-11-1995 24-04-1997 28-07-1994 23-03-1999
EP 0404210 A	27-12-1990	US 4866167 A AT 94213 T AU 5418586 A CA 1282357 A DE 3688985 D DE 3688985 T EP 0199439 A JP 61257200 A	12-09-1989 15-09-1993 04-09-1986 02-04-1991 14-10-1993 05-05-1994 29-10-1986 14-11-1989
EP 0300691 A	25-01-1989	HU 207197 B AT 72923 T CN 1036124 A,B DD 286097 A DE 3868751 A GR 3004781 T WO 8900380 A JP 1090106 A KR 9609483 B PL 161573 B SU 1836011 A US 4943307 A	29-03-1993 15-03-1992 11-10-1989 17-01-1991 09-04-1992 28-04-1993 26-01-1989 06-04-1989 20-07-1996 30-07-1993 23-08-1993 24-07-1990
US 2420295 A	13-05-1947	NONE	